Arcadia Biosciences, Inc. · NASDAQ:RKDA
Arcadia Biosciences — Q2 2017 Earnings Presentation
10 slides from Arcadia Biosciences's earnings presentation, Aug 10, 2017
Slide 1: Second Quarter 2017 Financial Results and Business Highlights
Second Quarter 2017 Financial Results and Business Highlights August 10, 2017
Slide 2: Forward-looking statements
Forward-looking statements “Safe Harbor” statement under the Private Securities Litigation Reform Act of 1995: This presentation c ontains forward-looking statements about the company and its products, including statements relating to components of the company’s long-term financial success;; the
Slide 3: Momentum continues in second quarter
Momentum continues in second quarter Revenue increased • Up 37% compared to Q2 last year and 28% YTD Operating expenses down • Decreased by 6% and 10% for the quarter and YTD, respectively Net loss significantly improved • Improved 12% for the quarter and 16% YTD compared to last year Products in pi
Slide 4: Recent achievements
Recent achievements Arcadia - Dow AgroSciences (DAS) wheat quality trait collaboration • Develop and commercialize non-GM nutrition trait in DAS germplasm HB4 stress tolerance trait completes US FDA safety review • FDA grants clearance for use in human food and animal feed • Will be a key referenc
Slide 5: Ingredients business progress continues
Ingredients business progress continues GLA safflower oil • Sales revenue on track for growth in 2017 • Market expansion into dog food, nutritional beverages and medical foods ARA safflower oil • Greenhouse trials produced desirable levels of ARA in safflower • Expanded trials to field in 2Q to vali
Slide 6: Ag productivity traits continue to advance
Ag productivity traits continue to advance HB4 stress-tolerant soybeans • FDA approval received on food and feed safety • Regulatory work for Europe and other countries continues with our Verdeca JV partner, Bioceres • Field trials in Argentina harvested, analysis underway Corn yield and stress tra
Slide 7: Revenue
Revenue Second Quarter First Half Favorable/ (Unfavorable) Favorable/ (Unfavorable) 2017 2016 $ % 2017 2016 $ % Product revenue 195 65 130 200% 400 320 80 25% License revenue 103 140 (37) (26)% 209 292 (83) (28)% Contract research and 693 516 177 34% 1,400 961 439 46% government grants Total revenue
Slide 8: Operating expenses
Operating expenses Second Quarter First Half Favorable/ (Unfavorable) Favorable/ (Unfavorable) 2017 2016 $ % 2017 2016 $ % Cost of product 116 35 (81) (231)% 222 182 (40) (22)% revenues R&D expense 1,669 2,216 547 25% 3,492 4,418 926 21% SG&A expense 2,943 2,759 (184) (7)% 5,995 6,195 200 3% Total o
Slide 9: Key financial results
Key financial results Second Quarter First Half Favorable/(Unfavorable) Favorable/(Unfavorable) 2017 2016 $ % 2017 2016 $ % Total revenues 991 721 270 37% 2,009 1,573 436 28% Cost of product revenues 116 35 (81) (231)% 222 182 (40) (22)% R&D expense 1,669 2,216 547 25% 3,492 4,418 926 21% SG&A expen
Slide 10: Thank you!
®D Arcadia BIOS CIEN CE S&S Thank you!